Advances in the application of anti-tuberculosis nanoscale drug delivery system targeting macrophages

doi:10.3969/j.issn.1000-6621.2020.04.018

Abstract

Abstract:

Mycobacterium tuberculosis (MTB) is a facultative intracellular parasite of macrophages, traditional anti-TB therapy have limitations such as long course of treatment, low bio-availability, high systemic toxicity and even may induce drug resistance. As a new method of anti-tuberculous drug administration, the nanoscale drug delivery system can deliver low-cost drugs into macrophages actively or passively to inhibit the replicate or latent MTB. This review explores the active and passive targeting mechanism of anti-tuberculosis nanoscale drug delivery system to macrophages, and advanced materials for assembling nanoscale delivery system. In addition, factors affecting targeted delivery efficiency and challenges are summarized.

Key words: Tuberculosis, Macrophages, Drug carriers, Molecular targeted therapy, Review literature as topic, Nanoscale drug delivery system

XIANG Hai-bin,LIANG Qiu-zhen,LI Xin-xia,SONG Xing-hua. Advances in the application of anti-tuberculosis nanoscale drug delivery system targeting macrophages[J]. Chinese Journal of Antituberculosis, 2020, 42(4): 398-403. doi: 10.3969/j.issn.1000-6621.2020.04.018

Figures/Tables 2

References 58

[1]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
[2]	Kalscheuer R, Palacios A, Anso I , et al. The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis. Biochem J, 2019,476(14):1995-2016.
[3]	Hmama Z, Pena-Diaz S, Joseph S , et al. Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis. Immunol Rev, 2015,264(1):220-232.
[4]	Mitchell G, Chen C, Portnoy DA . Strategies Used by Bacteria to Grow in Macrophages. Microbiol Spectr, 2016,4(3). doi: 10.1128/microbiolspec.MCHD-0012-2015.
[5]	Cardona P, Cardona PJ . Regulatory T Cells in Mycobacterium tuberculosis Infection. Front Immunol, 2019,10:2139.
[6]	Chai Q, Lu Z, Liu CH . Host defense mechanisms against Mycobacterium tuberculosis (Review). Cell Mol Life Sci, 2019. [Epub ahead of print]
[7]	de Martino M, Lodi L, Galli L , et al. Immune Response to Mycobacterium tuberculosis: A Narrative Review (Review). Front Pediatr, 2019,7:350.
[8]	Weiss G, Schaible UE . Macrophage defense mechanisms against intracellular bacteria. Immunol Rev, 2015,264(1):182-203.
[9]	Singh R, Dwivedi SP, Gaharwar US , et al. Recent updates on drug resistance in Mycobacterium tuberculosis (Review). J Appl Microbiol, 2019. [Epub ahead of print]
[10]	Lange C, Dheda K, Chesov D , et al. Management of drug-resistant tuberculosis. Lancet, 2019,394(10202):953-966.
[11]	Delogu G, Goletti D . The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol Suppl, 2014,91:11-16.
[12]	Costa-Gouveia J, Ainsa JA, Brodin P , et al. How can nano-particles contribute to antituberculosis therapy? Drug Discov Today, 2017,22(3):600-607.
[13]	Cheng H, Chawla A, Yang Y , et al. Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today, 2017,22(9):1336-1350.
[14]	Sahay G, Alakhova DY, Kabanov AV . Endocytosis of nanomedicines. J Control Release, 2010,145(3):182-195.
[15]	Patel S, Kim J, Herrera M , et al. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev, 2019,144:90-111.
[16]	Mir M, Ahmed N, Rehman AU . Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Bioin-terfaces, 2017,159:217-231.
[17]	Ding D, Zhu Q . Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater Sci Eng C Mater Biol Appl, 2018,92:1041-1060.
[18]	Xu Y, Kim CS, Saylor DM , et al. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories. J Biomed Mater Res B Appl Biomater, 2017,105(6):1692-1716.
[19]	Pandey R, Zahoor A, Sharma S , et al. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb), 2003,83(6):373-378.
[20]	Sharma A, Sharma S, Khuller GK . Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother, 2004,54(4):761-766.
[21]	Marcianes P, Negro S, Garcia-Garcia L , et al. Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis. Int J Nanomedicine, 2017,12:1959-1968.
[22]	Mignani S, Tripathi RP, Chen L , et al. New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers. Pharmaceutics, 2018, 10(3). pii: E105.
[23]	Bellini RG, Guimaraes AP, Pacheco MA , et al. Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer. J Mol Graph Model, 2015,60:34-42.
[24]	Dineshkumar P, Panneerselvam T, Brundavani KD , et al. Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers. Current Drug Therapy, 2017,12(2):115-126.
[25]	Klemens SP, Cynamon MH, Swenson CE , et al. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother, 1990,34(6):967-970.
[26]	Merchant Z, Buckton G, Taylor KM , et al. A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections. Curr Pharm Des, 2016,22(17):2577-2598.
[27]	Pinheiro M, Ribeiro R, Vieira A , et al. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther, 2016,10:2467-2475.
[28]	Costa A, Pinheiro M, Magalhaes J , et al. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev, 2016,102:102-115.
[29]	Anderson CF, Grimmett ME, Domalewski CJ , et al. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020,12(1):e1586.
[30]	Liang Z, Ni R, Zhou J , et al. Recent advances in controlled pulmonary drug delivery. Drug Discov Today, 2015,20(3):380-389.
[31]	Mosaiab T, Farr DC, Kiefel MJ , et al. Carbohydrate-based nanocarriers and their application to target macrophages and deliver antimicrobial agents. Adv Drug Deliv Rev, 2019,151/152:94-129.
[32]	Shivangi, Meena LS . A Novel Approach in Treatment of Tuberculosis by Targeting Drugs to Infected Macrophages Using Biodegradable Nanoparticles. Appl Biochem Biotechnol, 2018,185(3):815-821.
[33]	Lu E, Franzblau S, Onyuksel H , et al. Preparation of amino-glycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul, 2009,26(4):346-354.
[34]	El Zowalaty ME, Hussein Al Ali SH, Husseiny MI , et al. The ability of streptomycin-loaded chitosan-coated magnetic nanocomposites to possess antimicrobial and antituberculosis activities. Int J Nanomedicine, 2015,10:3269-3274.
[35]	Maiti D, Tong X, Mou X , et al. Carbon-Based Nanomaterials for Biomedical Applications: A Recent Study. Front Pharmacol, 2018,9:1401.
[36]	Zou F, Zhou H, Jeong DY , et al. Wrinkled Surface-Mediated Antibacterial Activity of Graphene Oxide Nanosheets. ACS Appl Mater Interfaces, 2017,9(2):1343-1351.
[37]	De Maio F, Palmieri V, Salustri A , et al. Graphene oxide prevents mycobacteria entry into macrophages through extracellular entrapment. Nanoscale Adv, 2019,1(4):1421-1431.
[38]	Palmieri V, Papi M, Conti C , et al. The future development of bacteria fighting medical devices: the role of graphene oxide. Expert Rev Med Devices, 2016,13(11):1013-1019.
[39]	De Maio F, Palmieri V, De Spirito M , et al. Carbon nanomaterials: a new way against tuberculosis. Expert Rev Med Devices, 2019,16(10):863-875.
[40]	Singh R, Nawale LU, Arkile M , et al. Chemical and biological metal nanoparticles as antimycobacterial agents: A comparative study. Int J Antimicrob Agents, 2015,46(2):183-188.
[41]	Olakanmi O, Kesavalu B, Pasula R , et al. Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes. Antimicrob Agents Chemother, 2013,57(12):6074-6080.
[42]	Narayanasamy P, Switzer BL, Britigan BE . Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages. Sci Rep, 2015,5:8824.
[43]	Choi SR, Britigan BE, Narayanasamy P. Ga(III) Nanoparticles Inhibit Growth of both Mycobacterium tuberculosis and HIV and Release of Interleukin-6 (IL-6) and IL-8 in Coinfected Macrophages. Antimicrob Agents Chemother, 2017, 61(4). pii: e02505-16.
[44]	Sato MR, Oshiro Junior JA, Machado RT , et al. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des Devel Ther, 2017,11:909-921.
[45]	Vieira ACC, Chaves LL, Pinheiro M , et al. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artif Cells Nanomed Biotechnol, 2018, 46 Suppl 1: S 653-663.
[46]	Maretti E, Costantino L, Rustichelli C , et al. Surface engineering of Solid Lipid Nanoparticle assemblies by methyl alpha-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm, 2017,528(1/2):440-451.
[47]	Gao Y, Sarfraz MK, Clas SD , et al. Hyaluronic Acid-Tocopherol Succinate-Based Self-Assembling Micelles for Targeted Delivery of Rifampicin to Alveolar Macrophages. J Biomed Nanotechnol, 2015,11(8):1312-1329.
[48]	Lemmer Y, Kalombo L, Pietersen RD , et al. Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis. J Control Release, 2015,211:94-104.
[49]	Mustafa S, Devi VK, Pai RS . Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles. Drug Deliv Transl Res, 2017,7(1):27-36.
[50]	Bharti S, Kaur G, Jain S , et al. Characteristics and mechanism associated with drug conjugated inorganic nanoparticles. J Drug Target, 2019,27(8):813-829.
[51]	Pi J, Shen L, Shen H , et al. Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M.tuberculosis killing efficiency. Mater Sci Eng C Mater Biol Appl, 2019,103:109777.
[52]	Costa A, Sarmento B, Seabra V . Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages. Eur J Pharm Sci, 2018,114:103-113.
[53]	Tukulula M, Gouveia L, Paixao P , et al. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages. Pharm Res, 2018,35(6):111.
[54]	Song X, Lin Q, Guo L , et al. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery. Pharm Res, 2015,32(5):1741-1751.
[55]	Saraogi GK, Sharma B, Joshi B , et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target, 2011,19(3):219-227.
[56]	Jain SK, Gupta Y, Ramalingam L , et al. Lactose-Conjugated PLGA Nanoparticles for Enhanced Delivery of Rifampicin to the Lung for Effective Treatment of Pulmonary Tuberculosis. PDA J Pharm Sci Technol, 2010,64(3):278-287.
[57]	Doshi N, Mitragotri S . Macrophages recognize size and shape of their targets. PLoS One, 2010,5(4):e10051.
[58]	Dua K, Rapalli VK, Shukla SD , et al. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches. Biomed Pharmacother, 2018,107:1218-1229.

分类	纳米载体	优点	缺点
聚合物	明胶、聚乳酸-羟基乙酸共聚物、聚乳酸、聚酸酐、聚丙烯酸酯、树枝状大分子	工艺简单;理化特性可控;生物稳定性高;多途径给药	体内降解速度慢;易蓄积;有机溶剂残留毒性
脂质体	长循环脂质体、糖基脂质体、pH敏感性脂质体	技术成熟;无有机溶剂制备;生物降解性及相容性高	物理稳定性差;半衰期短;药物负载能力低
多糖	藻酸盐、直链淀粉、壳聚糖、透明质酸、环糊精	本质为碳水化合物;毒性极低;廉价;生物相容性高;生物可降解性好	载药量和释放效率低
碳纳米	石墨、氧化石墨烯、碳纳米管、富勒烯和金刚石	载体表面可诱捕细菌且存在大量官能团;易被配体修饰	生物利用度低;生物稳定性差;急性炎症反应和进行性纤维化等毒性
金属载体	银纳米颗粒、镓纳米颗粒、金纳米颗粒、铁纳米颗粒	可干扰MTB代谢;具有抗菌活性	生物利用度低;时间相关的细胞毒性;重金属中毒

文献发表年份	配体	纳米载体	药物	粒径(nm)	电位(mV)	包封率(%)	载药率(%)	靶向细胞
2019	甘露糖	氧化石墨烯	利福平	50~300	-25	-^b	-^b	恒河猴巨噬细胞^[51]
2018	甘露糖	硬脂胺-脂质体	利福平	160~250	25.7	95.5	3.5	人THP1巨噬细胞系^[45]
2018	甘露糖	硬脂胺-脂质体	异烟肼	452~530	26.9~38.6	34.0~50.2	1.6~2.3	人THP1巨噬细胞系^[52]
2018	β-葡聚糖	PLGA	利福平	283.1	-28.6	-^b	1.1	人THP1巨噬细胞系^[53]
2017	聚乙二醇	PLGA	莫西沙星	112.16	4.76	76.55	86.75	巨噬细胞^[49]
2017	甘露糖	脂质体	利福平	720~1380	44.4~63.7^a	25.5~44.3	6.75~14.53	鼠J774巨噬细胞系^[46]
2016	甘露糖	硬脂胺-脂质体	利福布汀	213	37.6	90	-^b	鼠RAW264.7细胞系^[27]
2015	甘露糖	阳离子脂质	利福平	157.4	34.3	91.6	38.4~42.2	鼠肺泡NR8383细胞^[54]
2015	霉菌酸	PLGA	异烟肼	253~929	23.3~21.4^a	-^b	-^b	鼠骨髓巨噬细胞^[48]
2015	透明质酸	生育酚琥珀酸酯胶束	利福平	238~299	23.7~30.9^a	-^b	70.01~79.09	鼠肺泡MH-S巨噬细胞^[47]
2011	甘露糖	明胶	异烟肼	343	13.17	43.2	-^b	鼠J774巨噬细胞系^[55]
2010	乳糖	PLGA	利福平	184	-3.2	42.2	78.4±1.14	肺泡巨噬细胞^[56]